Resolutions adopted at the Extraordinary General Meeting of RTX A/S
Nørresundby, Denmark, 10 March 2023
Announcement no. 10/2023
Today, 10 March 2023, RTX A/S held an Extraordinary General Meeting at which the following resolutions were adopted based on proposals from the Board of Directors thereby confirming such resolutions adopted at the Annual General Meeting on 26 January 2023 and thus finally adopting the resolutions:
- Various changes to the Company’s Articles of Association to ensure that the Articles of Association are in line with the current practice among comparable companies (item 1).
- Authorization to attorney Henrik Møgelmose to inform the Danish Business Authority of the resolutions passed and to make any resulting changes to the Company’s Articles of Associations (item 2).
Yours sincerely
PETER THOSTRUPPETER RØPKE
Chair President & CEO
Questions and further information
CEO Peter Røpke, tel: +45 96 32 23 00
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Novo Nordisk A/S - share repurchase programme1.5.2024 14:30:46 CEST | Press release
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024. The programme is now concluded. Since the announcement 22 April 2024, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement2,133,5001,846,074,35122 April 202442,000859.5736,101,80523 April 202442,000881.9837,043,21124 April 202441,000885.2536,295,24925 April 202441,00
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics1.5.2024 14:01:00 CEST | Press release
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari’s Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari’s Chief Operating Officer effective today. In connection with Ms. Jacques’ departure, Akari’s board of directors (the “Board”) has appointed Dr. Patel as Interim Chief Executive Officer. Dr. Patel has served as a member of the Board since December 2023. “I am honored to be appointed interim CEO by the Akari Board of Directors. My immediate goals are timely completion of the previously announced merger between Akari Therapeutics and Peak Bio, implementation of the portfolio prioritization agreed upon by the boards of both companies whil
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity1.5.2024 14:00:00 CEST | Press release
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC (antibody drug conjugate) platform technology and Akari’s PAS-nomacopan Geographic Atrophy (GA) program. Peak’s ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari’s PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action b
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates1.5.2024 13:30:00 CEST | Press release
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024. Roluperidone NDA Update On February 27, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. The Company is in discussions with the FDA regarding the issues and clinical deficiencies raised in the CRL. Phase 1b Clinical Trial (MIN-101C18) In the first quarter of 2024, the Company completed a clinical trial initiated in October 2023 to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of the co-administration of roluperidone and olanzapi
EFRAG Selects Datamaran for Real-time Analysis of the Global ESG Landscape1.5.2024 13:01:17 CEST | Press release
The European Financial Reporting Advisory Group (EFRAG) selects Datamaran as its solution for data-driven ESG governance supporting the development of the European Sustainability Reporting Standards (ESRS) LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- The European Financial Reporting Advisory Group (EFRAG), Europe’s advisory body on financial and sustainability reporting, has chosen Datamaran, the market leader in Smart ESG (Environmental, Social, and Governance) software, as its solution for ESG governance and workflow management to support its research informing the development of the European Sustainability Reporting Standards (ESRS). Talking about the need for Datamaran, Patrick De Cambourg, the Chair of the EFRAG Sustainability Reporting Board, said: “EFRAG's mission is of crucial importance to make reliable and comparable disclosures on all material sustainability matters a reality, and ensure that financial disclosures and sustainability disclosures have the same level of quality and